RECURRENT CHOLANGIOCARCINOMA
Clinical trials for RECURRENT CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets bile duct cancer in small trial
Disease control OngoingThis phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC